Diabetic Macular Edema
Conditions
Interventions
Group A:intravitreal dexamethasone implant (OZURDEX)
Group B:intravitreal dexamethasone implant (OZURDEX) combined with laser photocoagulation
Sponsors
Shanghai Tongji Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects older than 18 years (type 1 or type 2 diabetes mellitus); 2. Subjects with HbA1c <= 10%; 3. Subjects with IOP <= 21mmhg; 4. DME patients with macular fovea were treated with anti VEGF drugs (including ranibizumab, arbacicept and conbercept) three times a month. Within three months after the last injection, macular edema persisted and the central retinal thickness of macular was more than 300 µ m; 5. After anti VEGF treatment, at least 3 months of washout period, the central macular retinal thickness was more than or equal to 300 µ M subjects.
Exclusion criteria
Exclusion criteria: 1. Patients with eye infection; 2. Patients who received intravitreal injection of anti VEGF or panretinal photocoagulation within 3 months; 3. Patients with intravitreal injection of glucocorticoid in the past 6 months; 4. Patients with macular traction; 5. Macular photocoagulation in the past; 6. Patients with proliferative diabetic retinopathy who did not receive adequate retinal photocoagulation; 7. Patients with previous high intraocular pressure or glaucoma; 8. Patients with obvious refractive stromal opacity; 9. Patients who underwent intraocular surgery in the past 6 months; 10. Patients with severe cardiovascular and cerebrovascular diseases and uncontrollable blood pressure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acurity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Central retinal thickness;Intraocular pressure;Progress of cataract;Number of intravitreal injections; | — |
Countries
China
Contacts
Public ContactYule Xu
Shanghai Tongji Hospital
Outcome results
None listed